Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?
Cooley M&A
JANUARY 22, 2025
Despite market speculation around potential sales of publicly traded biotech firms fueled by shifting regulatory environments, capital constraints and strategic realignments relatively few large transactions actually took place. Similarly, Novo Holdings $16.5
Let's personalize your content